Capstone Therapeutics says prior quarterly EPS figures should no longer be relied upon after share-count error
Reuters2026/08/12 11:34- Capstone Therapeutics flagged non-reliance on certain previously issued quarterly financial statements due to errors in weighted-average share counts.
- Issue affects basic and diluted net loss per share for quarters ended June 30, 2025, Sept. 30, 2025, and comparative March 31, 2025.
- Audit committee concurred on Aug. 10, 2026; amendments on Form 10-Q/A filed for June 30, 2025, Sept. 30, 2025, and March 31, 2026.
- Restated March 31, 2025 weighted-average shares to 1,555,566 from 5,190,251; net loss per share revised to $(1.56) from $(0.47).
- Management identified a material weakness in internal controls tied to EPS share-count computation; net loss and balance sheet amounts were not affected.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japanese Yen: Carry unwind supports gains against US Dollar - ING
Wall Street Brings the French Election to the Betting Table! Goldman Sachs and Deutsche Bank Package French Bank Debt, AT1 Bonds Become New Chips
Wall Street is turning next year's French presidential election into an investment strategy for traders, regardless of their expectations for the election outcome.
ABM Q3 FY26 GAAP net income rises 19% to $49.7 million; revenue climbs 4.2% to $2.3 billion
Kalshi's $400 million-plus monthly commodity trade volume outpaces early crypto growth
Crypto prices
More
